USE OF IMMUNOSUPPRESSANTS IN SSC PATIENTS WITH INTERSTITIAL LUNG DISEASE - RESULTS OF THE DESSCIPHER PROJECT OF THE EUSTAR GROUP

Scott Adler(CytomX Therapeutics (United States)), U.A. Walker(Felix Platter-Hospital), Dörte Huscher(Zimmer Biomet (Germany)), Marco Matucci‐Cerinic(Vita-Salute San Raffaele University), Yannick Allanore(Inserm), Oliver Distler(University Hospital of Zurich), CP Denton(The Royal Free Hospital), Gabriele Valentini(University of Campania "Luigi Vanvitelli"), László Czirják(University of Pecs), I Tarner, M. Frerix, Ulf Müeller-Ladner(Justus-Liebig-Universität Gießen), F. Galdo(Complexo Hospitalario Universitario A Coruña)
Unknown
March 1, 2014
Cited by 3

Related Papers

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis
|JAMA|2014|739
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
|Annals of the Rheumatic Diseases|2009|615